Delivering comprehensive care at every step of the patient journey with germline and tumor genomic insights to assess hereditary cancer risk, guide treatment selection, and evaluate recurrence risk—all in one streamlined solution.
Myriad Oncology offers comprehensive germline and tumor genomic tests that provide clinically actionable insights, helping to tailor treatments for each patient’s unique cancer journey—maximizing their chance for a healthier future.
I’m a provider
I’m a patient
From risk assessment to therapy selection, Myriad Oncology offers integrated germline and tumor genomic tests that enable a truly personalized approach to cancer prevention and treatment.
Myriad Oncology provides a comprehensive suite of services and workflow solutions that simplify germline and tumor genomic testing, all at no additional cost to the clinic or patient.
Pre- and post-test education as live, point-of-care sessions with a board-certified Genetic Counselor
Transparent pricing with personalized cost estimates, financial assistance, and other affordability options, including direct pay
Consolidated germline and tumor genomic results are available on average of 14 days after lab receives the sample
The Myriad Management Tool streamlines germline and tumor genomic results into an easy-to-follow report
Medical Science Liaison’s support providers and their teams in answering clinical, testing, and results-related questions
Myriad’s Variant Classification Program includes a Lifetime Reclassification Commitment to send amended reports if a variant of uncertain significance (VUS) is reclassified and is clinically actionable
Comprehensive germline and tumor genomic biomarker testing from a single, trusted source
Germline hereditary cancer test that evaluates 48 clinically actionable genes to provide a comprehensive, guideline-driven assessment across 11 common cancer sites.
Precise Tumor® is a pan-cancer, comprehensive laboratory test that uses state-of-the-art, next-generation sequencing to discover and target important variants within tumors.
Genomic prognostic test for patients newly diagnosed with early-stage, estrogen-receptor-positive, HER2-negative breast cancer.
Prolaris® is a molecular diagnostic test that helps determine the aggressiveness of a prostate cancer tumor to guide the best treatment decisions for prostate cancer patients.
The most comprehensive FDA-approved tumor test that determines HRD status in women with ovarian cancer.
FDA-approved germline companion diagnostic test for patients with breast, ovarian, pancreatic and prostate cancer.
FDA-approved assay to identify patients with ovarian cancer who may qualify for treatment with mirvetuximab*
Offered together with Precise Tumor™ to measure protein expression and identify patients who may benefit from immunotherapy
Many patients pay $0 for genetic testing.
Patients will know what their costs are—if any—before the test is run.
Myriad offers assistance to manage out-of-pocket costs as well as a direct pay option.
Myriad conducts industry-leading, innovative genetic research and testing to further the science of care. Our scientific studies have been published in prominent journals and at global conferences and feature breakthrough insights for improved patient treatments and outcomes.
Request more information from our team.
[email protected]
(800) 469-7423
Request more information about how Myriad Oncology can benefit you/your patients.
Request more information about how Myriad’s Oncology solutions can benefit you/your patients.
By submitting your personal information, you agree to be contacted with newsletters, marketing or promotional materials, and other information that may be of interest to you. You may opt-out of receiving communications from us by following the unsubscribe link or the instructions provided in the communication we send. For further information on our privacy practices and commitment to protecting your privacy, please visit our Privacy Notice.
Contact Information
Myriad Genetics, MyRisk, Precise Tumor, MyChoice, Prolaris, BRACAnalysis CDx, RiskScore, and their respective logos, are registered trademarks of Myriad Genetics, Inc. and its subsidiaries in the United States and other jurisdictions. EndoPredict and the EndoPredict logo are either trademarks or registered trademarks of Eurobio Scientific.